Sponsor Deadline
Posted: 5/9/2024

Mood and Psychosis Symptoms during the Menopause Transition (R01, R21 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications that will advance mechanistic and translational research on the onset and worsening of mood and psychotic disorders during the menopausal transition (or perimenopause). In particular, NIMH seeks research that will advance understanding of the underlying neurobiological and behavioral mechanisms of mood disruption and psychosis during the menopausal transition and that will identify novel targets for future mental health interventions or prevention efforts

This FOA uses the R01 grant mechanism, while the companion FOA (PAR-23-102) uses the R21 mechanism. Investigators proposing high risk/high reward projects, projects that lack preliminary data, or studies that utilize existing data may wish to apply using the R21 mechanism, while applicants with preliminary data who seek longer-term funding may wish to apply using the R01 mechanism.


  • R01 Due Dates: Feb 5, Jun 5, Oct 5

  • R21 Due Dates: Feb 16, Jun 16, Oct 16

PAR-23-097 Expiration Date New Date January 8, 2025 (Original Date: November 06, 2024) per issuance of NOT-MH-23-205

Areas of Interest

This FOA encourages applications from teams of diverse researchers. Teams may include but are not limited to members from the fields of neuroscience, engineering, endocrinology, epidemiology, reproductive medicine, gerontology, gynecology, pharmacology, psychiatry, and psychology with the expertise necessary to conduct rigorous research.